x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:12:48

ASH 2025: Aleta Biotherapeutics' Paul Rennert shares...

BiotechTV - News ·

2025/12/08

He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types.

en-us

00:07:02

ASH 2025: March Biosciences reported 5 complete...

BiotechTV - News ·

2025/12/08

Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.

en-us

00:15:36

Lyell Immunopharma CEO Lynn Seely discusses her...

BiotechTV - News ·

2025/12/08

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer.

en-us

00:10:13

ASH 2025: Rigel's CEO Raul Rodriguez discusses the...

BiotechTV - News ·

2025/12/07

He describes how Rigel became focused on both on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.

en-us

00:07:12

ASH 2025: CEO Will West describes how CellCentric is...

BiotechTV - News ·

2025/12/07

Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.

en-us

00:17:45

ASH 2025: Disc Medicine CEO John Quisel walks us...

BiotechTV - News ·

2025/12/07

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.

en-us

00:12:14

ASH 2025: Orca Bio has an April 6th PDUFA date from...

BiotechTV - News ·

2025/12/07

Co-Founder and CEO Nate Fernhoff walks us through this platform and the clinical data that Orca has previously announced, and new data at ASH. Plus, a journey through the patient experience of how this works.

en-us

00:11:07

ASH 2025: Kite Pharma EVP Cindy Perettie discusses...

BiotechTV - News ·

2025/12/07

She highlights anito-cell's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M.

en-us

00:11:32

ASH 2025: Von Willibrand disease is the most common...

BiotechTV - News ·

2025/12/06

Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

en-us

00:09:33

ASH 2025: Legend Biotech CEO Ying Huang discusses new...

BiotechTV - News ·

2025/12/06

He says he is confident in the commercial leadership profile that Carvykti has established, and walks us through potential follow-on pipeline programs.

en-us

00:15:18

Two veterans from MPM have launched a new VC firm...

BiotechTV - News ·

2025/12/05

Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

en-us

00:15:19

Oxford, UK based Accession Therapeutics raised $40M...

BiotechTV - News ·

2025/12/04

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

en-us

00:16:04

From London: Cancer Research Horizons takes research...

BiotechTV - News ·

2025/11/26

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

en-us

00:10:30

Jefferies London: Ipsen has done a string of deals...

BiotechTV - News ·

2025/11/19

He also goes over the company's programs in aesthetics, liver disease, and oncology.

en-us

00:11:17

Jefferies London: Terns' CEO Amy Burroughs previews...

BiotechTV - News ·

2025/11/19

The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.

en-us

00:12:29

Jefferies London: Affinity Asset Advisors' Patrick...

BiotechTV - News ·

2025/11/19

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes.

en-us

00:08:23

Jefferies London: Medicxi Announced a €500 Million...

BiotechTV - News ·

2025/11/19

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment.

en-us

00:14:08

Jefferies London: Olema Oncology more than doubled...

BiotechTV - News ·

2025/11/19

Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year.

en-us

00:13:27

Jefferies London: Zealand Pharma CEO Adam Steensberg...

BiotechTV - News ·

2025/11/18

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide.

en-us

00:09:25

Jefferies London: Nanobiotix has a new platform that...

BiotechTV - News ·

2025/11/18

CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal.

en-us

349 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter